Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 28:2022:5244538.
doi: 10.1155/2022/5244538. eCollection 2022.

Effects of Aerosol Inhalation Combined with Intravenous Drip of Polymyxin B on Bacterial Clearance, Symptoms Improvement, and Serum Infection Indexes in Patients with Pneumonia Induced by Multidrug-Resistant Gram-Negative Bacteria

Hanlu Lin  1 , Xiaobo Liu  1 , Pengfei Sun  1
Affiliations

Effects of Aerosol Inhalation Combined with Intravenous Drip of Polymyxin B on Bacterial Clearance, Symptoms Improvement, and Serum Infection Indexes in Patients with Pneumonia Induced by Multidrug-Resistant Gram-Negative Bacteria

Hanlu Lin et al. Emerg Med Int. .

Abstract

In recent years, the incidence of pneumonia caused by multidrug-resistant (MDR) Gram-negative bacteria (G-) has increased year by year. Polymyxin B has a good clinical effect in the treatment of MDR, but there is controversy about the administration route of this drug. In this study, we retrospectively analyzed the clinical data of 84 cases of MDR Gram-negative bacterial pneumonia, and aimed to explore the effects of aerosol inhalation combined with intravenous polymyxin B infusion on the bacterial clearance, symptom improvement, and serum infection indexes of MDR patients on the patients with Gram-negative (G-) bacterial pneumonia. The results show that aerosol inhalation combined with intravenous drip of polymyxin B can improve bacterial clearance rate, reduce levels of serum inflammatory factors, and improve clinical symptoms in patients with pneumonia induced by MDR G-bacteria.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Comparison of serum infection indicators between the two groups of patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Liu Y., Li R., Xiao X., Wang Z. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria. Critical Reviews in Microbiology . 2019;45(3):301–314. - PubMed
    1. Mousavi S. M., Babakhani S., Moradi L., et al. Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria. Current Microbiology . 2021;78(12):4023–4036. - PMC - PubMed
    1. Michalopoulos A., Kasiakou S. K., Mastora Z., Rellos K., Kapaskelis A. M., Falagas M. E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Critical Care . 2005;9(1):R53–R59. doi: 10.1186/cc3020. - DOI - PMC - PubMed
    1. Furtado G. H. C., D’Azevedo P. A., Santos A. F., Gales A. C., Pignatari A. C. C., Medeiros E. A. S. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. International Journal of Antimicrobial Agents . 2007;30(4):315–319. doi: 10.1016/j.ijantimicag.2007.05.017. - DOI - PubMed
    1. Doymaz M. Z., Karaaslan E. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria. Infectious Diseases . 2019;51(9):676–682. doi: 10.1080/23744235.2019.1640386. - DOI - PubMed

LinkOut - more resources